We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Blood Test for Receptor Predicts Prostate Cancer Treatment Response

By LabMedica International staff writers
Posted on 21 Sep 2014
Print article
Image: The ACD RNAscope 2.0 Brown kit for in situ hybridization (Photo courtesy of Advanced Cell Diagnostics).
Image: The ACD RNAscope 2.0 Brown kit for in situ hybridization (Photo courtesy of Advanced Cell Diagnostics).
Prostate cancer patients whose tumors contain a shortened receptor called androgen-receptor splice variant 7 messenger ribonucleic acid (AR-V7) are less likely to respond to two widely used drugs for metastatic prostate cancer.

The detection of AR-V7 in circulating tumor cells may be associated with resistance to enzalutamide and abiraterone in patients with castration-resistant prostate cancer. AR-V7 is the only known androgen-receptor variant encoding a functional protein product that is detectable in clinical specimens.

Scientists at the Johns Hopkins’ Kimmel Cancer Center (Baltimore, MD, USA) evaluated two groups of 31 men with prostate cancer that had spread and whose blood levels of prostate-specific antigen (PSA) were still rising despite low testosterone levels. Investigators gave each man either enzalutamide or abiraterone and tracked whether their PSA levels continued to rise, an indication that the drugs were not working.

Circulating tumor cell (CTC) analyses were conducted using the commercially-available Alere CTC AdnaTest platform (AdnaGen; Langenhagen, Germany). A Prostate Cancer Detect kit was used to make complementary DNA (cDNA) for detection of prostate cancer-associated RNA transcripts using multiplexed polymerase chain reaction (PCR) and the signals were detected by the Agilent Bioanalyzer (Agilent Technologies; Palo Alto, CA, USA). RNA in situ hybridization (RISH) was performed to detect the androgen receptor (AR) and AR-V7 on formalin-fixed paraffin-embedded (FFPE) tissue or cell pellet blocks using the ACD RNAscope 2.0 Brown kit (Advanced Cell Diagnostics; Hayward, CA, USA).

In the enzalutamide group, none of 12 patients whose blood samples tested positive for AR-V7 responded to the drug, compared with 10 responders among 19 men who had no AR-V7 detected. In the abiraterone group, none of six AR-V7-positive patients responded, compared with 17 responders among 25 patients lacking AR-V7. Enzalutamide and abiraterone target proteins called androgen receptors and block the receptors’ ability to activate prostate cancer cells. AR-V7 is a shortened form of the androgen receptor that lacks a binding spot targeted by enzalutamide and abiraterone. AR-V7 is therefore free to manipulate prostate cancer cells’ genetic material, which makes the cancer cells grow and spread.

Emmanuel S. Antonarakis, MD, assistant professor of oncology and lead author of the study said, “Patients whose blood samples contained AR-V7 got no benefit from either enzalutamide or abiraterone. This test could be used before starting enzalutamide or abiraterone therapy, and if the test shows the presence of AR-V7, patients may opt for a different therapy. It could also be used to monitor patients receiving enzalutamide or abiraterone for AR-V7, providing an indication these drugs may not work for much longer.” The study was published on September 3, 2014, in the New England Journal of Medicine.

Related Links:

Johns Hopkins’ Kimmel Cancer Center
AdnaGen 
Advanced Cell Diagnostics


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
HLX
Complement 3 (C3) Test
GPP-100 C3 Kit
New
Gold Member
Cancer Mutation Profiling Liquid Kit
OncoScreen Plus

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: The study showed the blood-based cancer screening test detects 83% of people with colorectal cancer with specificity of 90% (Photo courtesy of Guardant Health)

Blood Test Shows 83% Accuracy for Detecting Colorectal Cancer

Colorectal cancer is the second biggest cause of cancer deaths among adults in the U.S., with forecasts suggesting 53,010 people might die from it in 2024. While fewer older adults are dying from this... Read more

Hematology

view channel
Image: The Gazelle Hb Variant Test (Photo courtesy of Hemex Health)

First Affordable and Rapid Test for Beta Thalassemia Demonstrates 99% Diagnostic Accuracy

Hemoglobin disorders rank as some of the most prevalent monogenic diseases globally. Among various hemoglobin disorders, beta thalassemia, a hereditary blood disorder, affects about 1.5% of the world's... Read more

Microbiology

view channel
Image: The new platform is designed to perform blood-based diagnoses of nontuberculosis mycobacteria (Photo courtesy of 123RF)

New Blood Test Cuts Diagnosis Time for Nontuberculous Mycobacteria Infections from Months to Hours

Breathing in nontuberculous mycobacteria (NTM) is a common experience for many people. These bacteria are present in water systems, soil, and dust all over the world and usually don't cause any problems.... Read more

Industry

view channel
Image: These new assays are being developed for use on the recently introduced DxI 9000 Immunoassay Analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics

Beckman Coulter Diagnostics (Brea, CA, USA) and Fujirebio Diagnostics (Tokyo, Japan) have expanded their partnership focused on the development, manufacturing and clinical adoption of neurodegenerative... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.